Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China.

IF 2.7 3区经济学 Q1 ECONOMICS

Health Economics Review Pub Date : 2024-01-29 DOI:10.1186/s13561-024-00479-6

Pingyu Chen, Mengjie Luo, Yanqiu Chen, Yanlei Zhang, Chao Wang, Hongchao Li

{"title":"Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China.","authors":"Pingyu Chen, Mengjie Luo, Yanqiu Chen, Yanlei Zhang, Chao Wang, Hongchao Li","doi":"10.1186/s13561-024-00479-6","DOIUrl":null,"url":null,"abstract":"Background: Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human urinary kallidinogenase from China's healthcare system perspective.Methods: A combination of the decision tree and Markov model was constructed to evaluate the cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase in the treatment of acute ischemic stroke over a lifetime horizon. Efficacy data were derived from pivotal clinical trials of edaravone dexborneol and human urinary kallidinogenase (TASTE trial and RESK trial, respectively) and adjusted using matching-adjusted indirect comparison. Cost and health utility inputs were extracted from published literature and open databases. One-way deterministic sensitivity and probabilistic sensitivity analyses were performed to examine the robustness of the results.Results: Compared with human urinary kallidinogenase, edaravone dexborneol generated 0.153 incremental quality-adjusted life years (QALYs) with an incremental cost of ¥856, yielding an incremental cost-effectiveness ratio of ¥5,608 per QALY gained under the willingness-to-pay threshold (one-time gross domestic product per capita). Both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis demonstrated the robustness of the base case results.Conclusions: Edaravone dexborneol is a cost-effective treatment choice for acute ischemic stroke patients compared with human urinary kallidinogenase in China.","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"7"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10823610/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Economics Review","FirstCategoryId":"96","ListUrlMain":"https://doi.org/10.1186/s13561-024-00479-6","RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human urinary kallidinogenase from China's healthcare system perspective.

Methods: A combination of the decision tree and Markov model was constructed to evaluate the cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase in the treatment of acute ischemic stroke over a lifetime horizon. Efficacy data were derived from pivotal clinical trials of edaravone dexborneol and human urinary kallidinogenase (TASTE trial and RESK trial, respectively) and adjusted using matching-adjusted indirect comparison. Cost and health utility inputs were extracted from published literature and open databases. One-way deterministic sensitivity and probabilistic sensitivity analyses were performed to examine the robustness of the results.

Results: Compared with human urinary kallidinogenase, edaravone dexborneol generated 0.153 incremental quality-adjusted life years (QALYs) with an incremental cost of ¥856, yielding an incremental cost-effectiveness ratio of ¥5,608 per QALY gained under the willingness-to-pay threshold (one-time gross domestic product per capita). Both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis demonstrated the robustness of the base case results.

Conclusions: Edaravone dexborneol is a cost-effective treatment choice for acute ischemic stroke patients compared with human urinary kallidinogenase in China.

查看原文本刊更多论文

中国急性缺血性脑卒中治疗依达拉奉-右旋糖苷酶与人尿中凯利定肽原酶的成本效益对比。

背景：临床试验证明了依达拉奉-右旋糖苷酶治疗急性缺血性脑卒中的疗效。本研究旨在从中国医疗系统的角度确定依达拉奉-右旋糖苷酶与人尿凯利苷酶相比的成本效益：方法：结合决策树和马尔可夫模型，评估依达拉奉-右旋波旁醇与人尿凯利苷原酶在急性缺血性脑卒中治疗中的终生成本效益。疗效数据来自依达拉奉-右旋波旁醇和人尿凯利肽原酶的关键临床试验（分别为 TASTE 试验和 RESK 试验），并使用匹配调整间接比较法进行调整。成本和健康效用输入数据来自已发表的文献和开放式数据库。进行了单向确定性敏感性分析和概率敏感性分析，以检验结果的稳健性：结果：与人尿凯利苷原酶相比，依达拉奉-右旋波尼醇可增加0.153个质量调整生命年（QALY），增加成本为856日元，在支付意愿阈值（一次性人均国内生产总值）下，每获得一个QALY的增加成本效益比为5608日元。单向确定性敏感性分析和概率敏感性分析均证明了基本病例结果的稳健性：在中国，与人尿凯利苷原酶相比，依达拉奉-右旋倍他乐克是治疗急性缺血性脑卒中患者的一种经济有效的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Health Economics Review Multiple-

CiteScore

3.90

自引率

4.20%

发文量

审稿时长

13 weeks

期刊介绍： Health Economics Review is an international high-quality journal covering all fields of Health Economics. A broad range of theoretical contributions, empirical studies and analyses of health policy with a health economic focus will be considered for publication. Its scope includes macro- and microeconomics of health care financing, health insurance and reimbursement as well as health economic evaluation, health services research and health policy analysis. Further research topics are the individual and institutional aspects of health care management and the growing importance of health care in developing countries.